Vortex Biotechnology Corporation is a start-up company of the Cancer Drug Discovery CoEE. The company focuses on the development of inhibitors of Pim protein kinases, which are key regulators of prostate cancer and certain leukemias. Vortex designs, synthesizes, and evaluates proprietary Pim inhibitors, with the goal of moving an agent into clinical testing for the treatment of cancer.